Mental disorder treatment market

Mental Disorder Treatment Market, by Disorder Type (Depression, Bipolar Disorder, Schizophrenia, Dementia, Post-traumatic Stress Disorder, and Others), by Medication (Anti-depressants, Anti-anxiety, Mood Stabilizing Medication, and Antipsychotic Medications), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Request Free Sample

Dec 2020
CMI4326
175 Pages
Excel & Pdf
Pharmaceutical

Summary

A mental disorder is also called as mental illness or a psychiatric disorder. Mental disorders are generally defined according to how an individual behave, feels, perceives and thinks, and mental disorder occurs due to damage or problems associated with functions of brain. There are various types of mental disorders such as depression, bipolar disorder, schizophrenia and other psychoses, dementia, and developmental disorders including autism. These disorders can be treated with the help of various medications such as anti-depressants, antianxiety drugs and can also be treated with self-help therapies such as psychotherapy, brain stimulation treatments, and others.

The global mental disorder treatment market is estimated to be valued at US$ 48.4 Billion in 2020 and is expected to exhibit a CAGR of 6.6% during the forecast period (2020-2027).

Figure 1. Global Mental Disorder Treatment Market Value (US$ Bn), 2016-2027

The increasing prevalence of mental disorders such as depression is expected to propel growth of the global mental disorder treatment market during the forecast period. For instance, according to the World Health Organization report published in 2019, stated that depression is the most common mental disorder globally and around 264 million individuals suffered from depression globally, in the year 2019.

Furthermore, key companies focusing on product approvals by regulatory bodies for the treatment of mental disorders is expected to propel growth of the global mental disorder treatment market during the forecast period. For instance, in May 2019, Allergan plc. and Gedeon Richter Plc. announced that the U.S. Food and Drug Administration (FDA) approved its VRAYLAR (cariprazine) as a supplemental new drug application (sNDA) for the treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults.

Hydroxychloroquine Market Report Coverage

Report Coverage	Details
Base Year:	2019	Market Size in 2020:	US$ 48.4 Bn
Historical Data for:	2016 to 2019	Forecast Period:	2020 to 2027
Forecast Period 2020 to 2027 CAGR:	6.6%	2027 Value Projection:	US$ 75.7 Bn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC, Israel, and Rest of the Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Disorder Type: Depression, Bipolar Disorder, Schizophrenia, Dementia, Post-traumatic Stress Disorder, Others. By Medication: Anti-depressants, Anti-anxiety, Mood Stabilizing Medication, Antipsychotic Medications. By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:	Allergan plc, Eli Lilly and Company, VistaGen Therapeutics, Sanofi S.A, Novartis International AG, Mylan N.V., Amneal Pharmaceuticals LLC, Cipla Ltd, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Lupin Limited, Janssen Pharmaceutica, Bristol Myers Squibb, and Sumitomo Dainippon Pharma Co., Ltd
Growth Drivers:	Increasing prevalence of various mental disorders such as depression and bipolar disorders globally Key players focusing on inorganic strategies such collaborations and partnerships
Restraints & Challenges:	Anti-depressants can cause sexual disorders such as erectile dysfunction in male adults and antipsychotic medication leading to weight gain

Global Mental Disorder Treatment Market – Impact of Coronavirus (COVID-19)

Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency. According to the World Health Organization’s report, manifestation of coronavirus (COVID-19) has resulted in over 65.1 million infected individuals worldwide as of 4^th December, 2020.

The coronavirus (COVID-19) pandemic and resulting lockdown in various countries across the globe have impacted the financial status of major companies in the mental disorder treatment market. The private healthcare sector is one of the sectors, which has been majorly impacted by the COVID-19 pandemic. The pandemic has negatively impacted the global mental disorder treatment market in various aspects such as development, production, and supply of medicines and also affected growth of the pharmaceutical businesses of various companies across the globe due to lockdowns implemented by governments of several countries. The nationwide lockdowns have led to closure of industrial establishments, except manufacturing of essential commodities and disruption in supply chain of the raw materials and drugs for therapeutic use.

Figure 2. Global Mental Disorder Treatment Market Share (%), By Region, 2020

North America is expected to hold dominant position in the global mental disorder treatment market during the forecast period, owing to key companies focusing on inorganic strategies such as strategic collaborations for developing the treatment of various mental disorders such as depression and others. For instance, in June 2020, VistaGen Therapeutics, a pharmaceutical company in the U.S. and EverInsight Therapeutic entered into a strategic collaboration to develop and commercialize ph94b for anxiety disorders in greater China, South Korea, and Southeast Asia.

Key Players

Major players operating in the global mental disorder treatment market include Allergan plc, Eli Lilly and Company, VistaGen Therapeutics, Sanofi S.A, Novartis International AG, Mylan N.V., Amneal Pharmaceuticals LLC, Cipla Ltd, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Lupin Limited, Janssen Pharmaceutica, Bristol Myers Squibb, and Sumitomo Dainippon Pharma Co., Ltd

Table of Content

*Browse 33 market data tables and 32 figures on " Mental Disorder Treatment Market – Global forecast to 2027”.

N/A

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the market during the forecast period (2020-2027)?

The global mental disorder treatment market size is estimated to be valued at US$ 48.4 billion in 2020 and is expected to exhibit a CAGR of 6.6 % between 2020 and 2027.

What are the major drivers for growth of the global mental disorder treatment market?

Increasing prevalence of various mental disorders such as depression, bipolar disorders globally and key players focusing on inorganic strategies such collaborations and partnerships are expected to drive growth of the global mental disorder treatment market over the forecast period.

Which is the leading disorder type segment in the global mental disorder treatment market?

Depression segment is estimated to hold major market share in the global mental disorder treatment market during the forecast period, owing to an increasing prevalence of depression in individuals globally.

Which is the leading medication segment in the global mental disorder treatment market?

Anti-depressants segment is estimated to hold major market share in the global mental disorder treatment market during the forecast period, owing to rising incidence of depression in children and adults globally.

Which region is estimated to generate the largest market share in 2020 in the global mental disorder treatment market?

North America is estimated to generate largest revenue share in 2020 in the global mental disorder treatment market.

What are the key factors hampering growth of the market?

Anti-depressants can cause sexual disorders such as erectile dysfunction in male adults and antipsychotic medication leading to weight gain are the key factors that are expected to hamper growth of the market.